Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide with or without Daratumumab in Relapsed/Refractory Multiple Myeloma
NCT01946477Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- May 2014
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies, Recombinant Proteins and Enzymes, Molecular Glues
- Countries
- 4
01
Overview
A Phase 2 trial of pomalidomide, daratumumab in multiple myeloma (MM), sponsored by Celgene Corporation. Started May 2014; status: completed.
02
Drugs
pomalidomidedaratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01946477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01946477.